Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian M. Culley acquired 40,000 shares of the stock in a transaction dated Thursday, November 21st. The stock was purchased at an average cost of $0.60 per share, with a total value of $24,000.00. Following the purchase, the chief executive officer now directly owns 194,842 shares of the company's stock, valued at $116,905.20. This trade represents a 25.83 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Lineage Cell Therapeutics stock traded down $0.02 on Friday, hitting $0.58. The stock had a trading volume of 1,110,161 shares, compared to its average volume of 825,337. Lineage Cell Therapeutics, Inc. has a twelve month low of $0.56 and a twelve month high of $1.61. The company has a market capitalization of $110.32 million, a P/E ratio of -5.00 and a beta of 1.28.

Separately, Craig Hallum initiated coverage on Lineage Cell Therapeutics in a research note on Tuesday, August 20th. They issued a "buy" rating and a $4.00 price objective for the company.

Get Our Latest Report on LCTX

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Lineage Cell Therapeutics during the 3rd quarter valued at approximately $46,000. XTX Topco Ltd acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $61,000. GSA Capital Partners LLP acquired a new stake in Lineage Cell Therapeutics during the 3rd quarter valued at approximately $84,000. Rhumbline Advisers boosted its holdings in shares of Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company's stock worth $132,000 after buying an additional 17,411 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company's stock worth $192,000 after buying an additional 159,924 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company's stock.

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Lineage Cell Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.

While Lineage Cell Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.